General Proximity

General Proximity is a San Francisco, California-based biotechnology company that develops next-generation induced-proximity medicines using its proprietary OmniTAC platform to target previously undruggable proteins. The seed-stage firm operates with approximately 15 employees and recently emerged from stealth in early 2025 with $16 million in venture capital funding alongside non-dilutive grants from the National Cancer Institute and ARPA-H. The company is backed by prominent institutional investors including Y Combinator, Felicis, and age1, and it actively collaborates with major healthcare organizations such as Johnson & Johnson and UCSF. General Proximity focuses on creating bifunctional therapeutics for oncology, cardiometabolic disease, and neurodegeneration, leveraging a specialized leadership team that has collectively contributed to more than 40 FDA-approved medicines and holds 247 patents. The biotechnology organization was originally founded in 2019 by chief executive officer Armand B. Cognetta III.

General Proximity is a seed-stage biotechnology platform company founded in 2019 that pioneers the next generation of induced proximity medicines targeting traditionally undruggable proteins implicated in cancer, cardiometabolic disease, neurodegeneration, and longevity. Its proprietary OmniTAC platform enables precise and selective modulation of disease-driving proteins by controlling biological proximity, creating new therapeutic opportunities beyond conventional drug discovery. The company serves pharmaceutical partners and research institutions aiming to develop innovative therapies for complex diseases, addressing a potential market exceeding $250 billion annually. General Proximity has demonstrated strong growth momentum, raising $16 million in funding led by Felicis and Y Combinator, and recently entered a strategic multi-target collaboration with Daiichi Sankyo to advance oncology therapeutics using its platform[1][2][3][7].

Founded by Armand B. Cognetta III, PhD, General Proximity emerged from stealth in early 2025 after several years of development. The idea originated from the recognition that biological proximity—the interaction or nearness of molecules—is a master regulator of biology, and that controlling this proximity could unlock modulation of previously undruggable targets. Early traction includes securing seed funding from top investors like Y Combinator and Felicis, and winning multiple “Golden Tickets” from big pharma, validating its technology and approach. The collaboration with Daiichi Sankyo marks a pivotal moment, expanding its reach into oncology and reinforcing its platform’s potential to generate first-in-class therapeutic candidates[1][2][3][6].

Core Differentiators

• Proprietary OmniTAC platform: Enables unbiased discovery and precise control of effector-target pairs for induced proximity medicines, allowing modulation of undruggable proteins.
• Next-generation induced proximity approach: Advances beyond traditional small-molecule drug discovery by harnessing biological proximity as a therapeutic mechanism.
• Strong investor and partner network: Backed by Y Combinator, Felicis, age1, Wilson Sonsini, Modi Ventures, and collaborating with Daiichi Sankyo.
• Broad therapeutic focus: Oncology, cardiometabolic disease, neurodegeneration, and longevity, addressing large unmet medical needs.
• Validated by industry recognition: Awarded multiple big pharma “Golden Tickets” and strategic partnerships confirming platform value.
• Seed-stage agility with deep scientific expertise: Led by founder Armand Cognetta, combining cutting-edge science with startup innovation[1][2][4][5].

Role in the Broader Tech Landscape

General Proximity rides the rising trend of induced proximity medicines, a transformative modality in drug discovery that leverages the cell’s own machinery to target disease proteins previously considered undruggable. This approach is gaining momentum as it offers a new paradigm beyond the classical “lock and key” model, enabling therapies with potentially higher efficacy and specificity. The timing is critical due to advances in molecular biology, protein degradation technologies, and computational drug discovery, alongside growing pharmaceutical interest and investment in proximity-based therapeutics. General Proximity’s platform contributes to expanding the therapeutic landscape, influencing both biotech innovation and pharmaceutical pipelines by enabling novel mechanisms of action and accelerating drug discovery[1][2][7][8].

Quick Take & Future Outlook

Looking ahead, General Proximity is poised to expand its pipeline across multiple disease areas, leveraging its OmniTAC platform to discover novel effector-target pairs and develop first-in-class medicines. The ongoing collaboration with Daiichi Sankyo is likely to catalyze further validation and commercialization opportunities, particularly in oncology. Trends shaping its journey include increasing adoption of proximity-based modalities, integration of AI-driven discovery tools, and growing demand for therapies addressing complex, undruggable targets. As the field matures, General Proximity’s influence may grow from a pioneering startup to a key platform provider shaping the future of precision medicine by controlling biological proximity to modulate disease[1][2][5]. This aligns with its mission to lower the global disease burden by redefining therapeutic discovery through induced proximity.